{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Anti-proliferative", "Apoptosis", "EGFR inhibitors", "Essential dynamics", "Semi synthesis", "Triple-negative breast cancer"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "37162644", "DateCompleted": {"Year": "2024", "Month": "07", "Day": "24"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "24"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "05", "Day": "10"}], "Language": ["eng"], "ELocationID": ["10.1007/s11030-023-10644-4"], "Journal": {"ISSN": "1573-501X", "JournalIssue": {"Volume": "28", "Issue": "3", "PubDate": {"Year": "2024", "Month": "Jun"}}, "Title": "Molecular diversity", "ISOAbbreviation": "Mol Divers"}, "ArticleTitle": "New apoptotic anti-triple-negative breast cancer theobromine derivative inhibiting EGFRWT and EGFR<sup>T790M</sup>: in silico and in vitro evaluation.", "Pagination": {"StartPage": "1153", "EndPage": "1173", "MedlinePgn": "1153-1173"}, "Abstract": {"AbstractText": ["A new theobromine-derived EGFR inhibitor (2-(3,7-Dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)-N-(2,6-dimethylphenyl)acetamide) has been developed that has the essential structural characteristics to interact with EGFR's pocket. The designed compound is 2,6-di ortho methylphenyl)acetamide derivative of the well-known alkaloid, theobromine, (T-1-DOMPA). Firstly, deep DFT studies have been conducted to study the optimized chemical structure, molecular orbital and chemical reactivity analysis of T-1-DOMPA. Then, T-1-DOMPA's anticancer potentialities were estimated first through a structure-based computational approach. Utilizing molecular docking, molecular dynamics, MD, simulations over 100\u00a0ns, MM-PBSA and PLIP studies, T-1-DOMPA bonded to and inhibited the EGFR protein effectively. Subsequently, the ADMET profiles of T-1-DOMPA were computed before preparation, and its drug-likeness was anticipated. Therefore, T-1-DOMPA was prepared for the purposes of scrutinizing both the design and the results obtained in silico. The in vitro potential of T-1-DOMPA against triple-negative breast cancer cell lines, MDA- MB-231, was very promising with an IC<sub>50</sub> value of1.8\u00a0\u00b5M, comparable to the reference drug (0.9\u00a0\u00b5M), and a much higher selectivity index of 2.6. Interestingly, T-1-DOMPA inhibited three other cancer cell lines (CaCO-2, HepG-2, and A549) with IC<sub>50</sub> values of 1.98, 2.53, and 2.39\u00a0\u00b5M exhibiting selectivity index values of 2,4, 1.9, and 2, respectively. Additionally, T-1-DOMPA prevented effectively the MDA-MB-231cell line's healing and migration abilities. Also, T-1-DOMPA's abilities to induce apoptosis were confirmed by acridine orange/ethidium bromide (AO/EB) staining assay. Finally, T-1-DOMPA caused an up-regulation of the gene expression of the apoptotic gene, Caspase-3, in the treated MDA-MB-231cell."], "CopyrightInformation": "\u00a9 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt. ibrahimeissa@azhar.edu.eg."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt."}], "LastName": "G Yousef", "ForeName": "Reda", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt."}], "LastName": "Elkady", "ForeName": "Hazem", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh, 11671, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Aisha A", "Initials": "AA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry Department, Faculty of Science, New Valley University, El-Kharja, 72511, Egypt."}], "LastName": "Husein", "ForeName": "Dalal Z", "Initials": "DZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biophysics Department, Faculty of Science, Cairo University, Cairo, 12613, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab City, Alexandria, Egypt."}, {"Identifier": [], "Affiliation": "Pharmaceutical and Fermentation Industries Development Center, City of Scientific Research and Technological Applications (SRTA City), New Borg El-Arab City, 21934, Alexandria, Egypt."}], "LastName": "El-Deeb", "ForeName": "Nehal", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Nucleic Acids Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab City, 21934, Alexandria, Egypt."}], "LastName": "Kenawy", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt."}, {"Identifier": [], "Affiliation": "School of Biotechnology, Badr University in Cairo, Badr City, 11829, Egypt."}], "LastName": "Eldehna", "ForeName": "Wagdy M", "Initials": "WM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh, 13713, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab City, Alexandria, Egypt. ametwaly@azhar.edu.eg."}, {"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, 11884, Egypt. ametwaly@azhar.edu.eg."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Netherlands", "MedlineTA": "Mol Divers", "NlmUniqueID": "9516534", "ISSNLinking": "1381-1991"}, "ChemicalList": [{"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "OBD445WZ5P", "NameOfSubstance": "Theobromine"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Triple Negative Breast Neoplasms"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Theobromine"}, {"QualifierName": [], "DescriptorName": "Molecular Dynamics Simulation"}, {"QualifierName": [], "DescriptorName": "Computer Simulation"}, {"QualifierName": ["pharmacology", "chemistry"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Lyons TG (2019) Targeted therapies for triple-negative breast cancer. Curr Treat Options Oncol 20(11):1\u201313", "ArticleIdList": ["10.1007/s11864-019-0682-x"]}, {"Citation": "Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni LJ (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13(11):674\u2013690", "ArticleIdList": ["27184417", "5461122", "10.1038/nrclinonc.2016.66"]}, {"Citation": "Engel T (2006) Basic overview of chemoinformatics. J Chem Inf Model 46(6):2267\u20132277", "ArticleIdList": ["17125169", "10.1021/ci600234z"]}, {"Citation": "Xu J, Hagler A (2002) Chemoinformatics and drug discovery. Molecules 7(8):566\u2013600", "ArticleIdList": ["6146447", "10.3390/70800566"]}, {"Citation": "March-Vila E, Pinzi L, Sturm N, Tinivella A, Engkvist O, Chen H et al (2017) On the integration of in silico drug design methods for drug repurposing. Front Pharmacol 8:298", "ArticleIdList": ["28588497", "5440551", "10.3389/fphar.2017.00298"]}, {"Citation": "Eissa IH, Alesawy MS, Saleh AM, Elkaeed EB, Alsfouk BA, El-Attar A-AM et al (2022) Ligand and structure-based in silico determination of the most promising SARS-CoV-2 nsp16-nsp10 2\u2032-o-Methyltransferase complex inhibitors among 3009 FDA approved drugs. Molecules 27(7):2287", "ArticleIdList": ["35408684", "9000629", "10.3390/molecules27072287"]}, {"Citation": "Suleimen YM, Jose RA, Suleimen RN, Arenz C, Ishmuratova M, Toppet S et al (2022) Isolation and in silico anti-SARS-CoV-2 papain-like protease potentialities of two rare 2-phenoxychromone derivatives from Artemisia spp. Molecules 27(4):1216", "ArticleIdList": ["35209006", "8879996", "10.3390/molecules27041216"]}, {"Citation": "Suleimen YM, Jose RA, Suleimen RN, Arenz C, Ishmuratova MY, Toppet S et al (2022) Jusanin, a new flavonoid from Artemisia commutata with an in silico inhibitory potential against the SARS-CoV-2 main protease. Molecules 27(5):1636", "ArticleIdList": ["35268738", "8911936", "10.3390/molecules27051636"]}, {"Citation": "Mohammed SO, El Ashry ESH, Khalid A, Amer MR, Metwaly AM, Eissa IH et al (2022) Expression, purification, and comparative inhibition of helicobacter pylori urease by regio-selectively alkylated benzimidazole 2-thione derivatives. Molecules 27(3):865", "ArticleIdList": ["35164122", "8838460", "10.3390/molecules27030865"]}, {"Citation": "Suleimen YM, Jose RA, Suleimen RN, Ishmuratova MY, Toppet S, Dehaen W et al (2022) Isolation and in silico SARS-CoV-2 main protease inhibition potential of jusan coumarin, a new dicoumarin from Artemisia glauca. Molecules 27(7):2281", "ArticleIdList": ["35408682", "9000794", "10.3390/molecules27072281"]}, {"Citation": "Eissa IH, Khalifa MM, Elkaeed EB, Hafez EE, Alsfouk AA, Metwaly AM (2021) In silico exploration of potential natural inhibitors against SARS-Cov-2 nsp10. Molecules 26(20):6151", "ArticleIdList": ["34684735", "8539059", "10.3390/molecules26206151"]}, {"Citation": "Elkaeed EB, Elkady H, Belal A, Alsfouk BA, Ibrahim TH, Abdelmoaty M et al (2022) Multi-phase in silico discovery of potential SARS-CoV-2 RNA-dependent RNA polymerase inhibitors among 3009 clinical and FDA-approved related drugs. Processes 10(3):530", "ArticleIdList": ["10.3390/pr10030530"]}, {"Citation": "Alesawy MS, Elkaeed EB, Alsfouk AA, Metwaly AM, Eissa I (2021) In silico screening of semi-synthesized compounds as potential inhibitors for SARS-CoV-2 papain-like protease: pharmacophoric features, molecular docking, ADMET. Tox DFT Stud Mol 26(21):6593"}, {"Citation": "Newman DJ, Cragg GM (2016) Natural products as sources of new drugs from 1981 to 2014. J Nat Prod 79(3):629\u2013661", "ArticleIdList": ["26852623", "10.1021/acs.jnatprod.5b01055"]}, {"Citation": "da Rosa R, Schenkel EP, Bernardes LSC (2020) Semisynthetic and newly designed derivatives based on natural chemical scaffolds: moving beyond natural products to fight Trypanosoma cruzi. Phytochem Rev 19(1):105\u2013122", "ArticleIdList": ["10.1007/s11101-020-09659-8"]}, {"Citation": "S\u00e1nchez-Recillas A, Navarrete-V\u00e1zquez G, Hidalgo-Figueroa S, Rios MY, Ibarra-Barajas M, Estrada-Soto S (2014) Semisynthesis, ex vivo evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugs. Eur J Med Chem 77:400\u2013408", "ArticleIdList": ["24681028", "10.1016/j.ejmech.2014.03.029"]}, {"Citation": "Kumar P, Aggarwal RJ (2016) An overview of triple-negative breast cancer. Arch Gynecol Obstet 293(2):247\u2013269", "ArticleIdList": ["26341644", "10.1007/s00404-015-3859-y"]}, {"Citation": "Bergin AR, Loi S (2019) Triple-negative breast cancer: recent treatment advances. F1000Research 8"}, {"Citation": "Ueno NT, Zhang DJ (2011) Targeting EGFR in triple negative breast cancer. J Cancer 2:324", "ArticleIdList": ["21716849", "3119395", "10.7150/jca.2.324"]}, {"Citation": "Nakai K, Hung M-C, Yamaguchi HJ (2016) A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res 6(8):1609", "ArticleIdList": ["27648353", "5004067"]}, {"Citation": "P\u00e9rez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22(16):3238\u20133247", "ArticleIdList": ["15310767", "10.1200/JCO.2004.11.057"]}, {"Citation": "Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP et al (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non\u2013small cell lung cancer: a randomized trial. JAMA 290(16):2149\u20132158", "ArticleIdList": ["14570950", "10.1001/jama.290.16.2149"]}, {"Citation": "McIntyre J, Castaner J, Leeson P (2005) Canertinib dihydrochloride. Drugs Future 30:771\u2013779", "ArticleIdList": ["10.1358/dof.2005.030.08.927254"]}, {"Citation": "Li Q, Zhang T, Li S, Tong L, Li J, Su Z et al (2019) Discovery of potent and noncovalent reversible EGFR kinase inhibitors of EGFRL858R/T790M/C797S. ACS Med Chem Lett 10(6):869\u2013873", "ArticleIdList": ["31223440", "6580378", "10.1021/acsmedchemlett.8b00564"]}, {"Citation": "Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al (2005) Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci 102(21):7665\u20137670", "ArticleIdList": ["15897464", "1129023", "10.1073/pnas.0502860102"]}, {"Citation": "Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A et al (2013) LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol 31(27):3335\u20133341", "ArticleIdList": ["23816963", "10.1200/JCO.2012.45.0981"]}, {"Citation": "Xu X (2015) Parallel phase 1 clinical trials in the US and in China: accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance. Chin J Cancer 34(3):27", "ArticleIdList": ["26152224", "4593347", "10.1186/s40880-015-0029-3"]}, {"Citation": "Park K, Lee J-S, Lee KH, Kim J-H, Cho BC, Min YJ et al (2016) Olmutinib (BI 1482694; HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: efficacy and safety at the RP2D. J Clin Oncol 34:9055", "ArticleIdList": ["10.1200/JCO.2016.34.15_suppl.9055"]}, {"Citation": "Todsaporn D, Mahalapbutr P, Poo-Arporn RP, Choowongkomon K, Rungrotmongkol T (2022) Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR. Comput Biol Med 147:105787", "ArticleIdList": ["35803080", "10.1016/j.compbiomed.2022.105787"]}, {"Citation": "Kobayashi Y, Fujino T, Nishino M, Koga T, Chiba M, Sesumi Y et al (2018) EGFR T790M and C797S mutations as mechanisms of acquired resistance to dacomitinib. J Thorac Oncol 13(5):727\u2013731", "ArticleIdList": ["29410323", "10.1016/j.jtho.2018.01.009"]}, {"Citation": "Botting GM, Rastogi I, Chhabra G, Nlend M, Puri NJ (2015) Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer. PLoS ONE 10(8):e0136155", "ArticleIdList": ["26301867", "4547756", "10.1371/journal.pone.0136155"]}, {"Citation": "Gusenbauer S, Vlaicu P, Ullrich A (2013) HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 32(33):3846\u20133856", "ArticleIdList": ["23045285", "10.1038/onc.2012.396"]}, {"Citation": "Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T et al (2012) Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44(8):852\u2013860", "ArticleIdList": ["22751098", "3408577", "10.1038/ng.2330"]}, {"Citation": "Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C et al (2011) EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 71(2):241\u2013243", "ArticleIdList": ["21168933", "10.1016/j.lungcan.2010.11.014"]}, {"Citation": "Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T et al (2009) PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res 69(8):3256\u20133261", "ArticleIdList": ["19351834", "2849653", "10.1158/0008-5472.CAN-08-4055"]}, {"Citation": "Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS et al (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18(4):521\u2013528", "ArticleIdList": ["22426421", "10.1038/nm.2713"]}, {"Citation": "Zhang H, Wang Y-J, Zhang Y-K, Wang D-S, Kathawala RJ, Patel A et al (2014) AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Lett 350(1\u20132):61\u201368", "ArticleIdList": ["24747122", "10.1016/j.canlet.2014.04.008"]}, {"Citation": "Levin PA, Mayer M, Hoskin S, Sailors J, Oliver DH, Gerber DE (2015) Histologic transformation from adenocarcinoma to squamous cell carcinoma as a mechanism of resistance to EGFR inhibition. J Thorac Cancer 10(9):e86\u2013e88"}, {"Citation": "Mowafy S, Galanis A, Doctor ZM, Paranal RM, Lasheen DS, Farag NA et al (2016) Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives. Biorg Med Chem 24(16):3501\u20133512", "ArticleIdList": ["10.1016/j.bmc.2016.05.063"]}, {"Citation": "Zhao Z, Wu H, Wang L, Liu Y, Knapp S, Liu Q et al (2014) Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery? ACS Chem Biol 9(6):1230\u20131241", "ArticleIdList": ["24730530", "4068218", "10.1021/cb500129t"]}, {"Citation": "Gandin V, Ferrarese A, Dalla Via M, Marzano C, Chilin A, Marzaro G (2015) Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N\u2019-[4-(pyrimidin-4-ylamino) phenyl] urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Sci Rep 5:16750", "ArticleIdList": ["26568452", "4645160", "10.1038/srep16750"]}, {"Citation": "Liu Y, Gray NS (2006) Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2(7):358\u2013364", "ArticleIdList": ["16783341", "10.1038/nchembio799"]}, {"Citation": "Furet P, Caravatti G, Lydon N, Priestle JP, Sowadski JM, Trinks U et al (1995) Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput Aided Mol Des 9(6):465\u2013472", "ArticleIdList": ["8789188", "10.1007/BF00124317"]}, {"Citation": "Traxler P, Bold G, Frei J, Lang M, Lydon N, Mett H et al (1997) Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino) pyrazolo [3, 4-d] pyrimidines. J Med Chem 40(22):3601\u20133616", "ArticleIdList": ["9357527", "10.1021/jm970124v"]}, {"Citation": "Elkaeed EB, Yousef RG, Elkady H, Alsfouk AA, Husein DZ, Ibrahim IM et al (2022) New anticancer theobromine derivative targeting egfrwt and egfrt790m: design, semi-synthesis, in silico, and in vitro anticancer studies. Molecules 27(18):5859", "ArticleIdList": ["36144596", "9500845", "10.3390/molecules27185859"]}, {"Citation": "Husein DZ, Hassanien R, Khamis M (2021) Cadmium oxide nanoparticles/graphene composite: synthesis, theoretical insights into reactivity and adsorption study. Rsc Adv 11(43):27027\u201327041", "ArticleIdList": ["35480026", "9037664", "10.1039/D1RA04754J"]}, {"Citation": "Wang T, Husein DZ (2022) Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: disposing of waste with waste. Environ Sci Pollut Res 1\u201328"}, {"Citation": "Nossier ES, Alasfoury RA, Hagras M, El-Manawaty M, Sayed SM, Ibrahim IM et al (2022) Modified pyrido [2, 3-d] pyrimidin-4 (3H)-one derivatives as EGFRWT and EGFRT790M inhibitors: design, synthesis, and anti-cancer evaluation. J Mol Struct 1270:133971", "ArticleIdList": ["10.1016/j.molstruc.2022.133971"]}, {"Citation": "Ferreira LL, Andricopulo AD (2019) ADMET modeling approaches in drug discovery. Drug Discov Today 24(5):1157\u20131165", "ArticleIdList": ["30890362", "10.1016/j.drudis.2019.03.015"]}, {"Citation": "Dearden JC (2003) In silico prediction of drug toxicity. J Comput-Aided Mol Des 17(2):119\u2013127", "ArticleIdList": ["13677480", "10.1023/A:1025361621494"]}, {"Citation": "Idakwo G, Luttrell J, Chen M, Hong H, Zhou Z, Gong P et al (2018) A review on machine learning methods for in silico toxicity prediction. J Environ Sci Health Part C 36(4):169\u2013191", "ArticleIdList": ["10.1080/10590501.2018.1537118"]}, {"Citation": "Elkaeed EB, Taghour MS, Mahdy HA, Eldehna WM, El-Deeb NM, Kenawy AM et al (2022) New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. J Enzym Inhib Med Chem 37(1):2191\u20132205", "ArticleIdList": ["10.1080/14756366.2022.2110869"]}, {"Citation": "Elwan A, Abdallah AE, Mahdy HA, Dahab MA, Taghour MS, Elkaeed EB et al (2022) Modified benzoxazole-based VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, and anti-proliferative evaluation. Molecules 27(15):5047", "ArticleIdList": ["35956997", "9370530", "10.3390/molecules27155047"]}, {"Citation": "Elkaeed EB, Youssef FS, Eissa IH, Elkady H, Alsfouk AA, Ashour ML et al (2022) Multi-step in silico discovery of natural drugs against COVID-19 targeting main protease. Int J Mol Sci 23(13):6912", "ArticleIdList": ["35805916", "9266348", "10.3390/ijms23136912"]}, {"Citation": "Elkaeed EB, Yousef RG, Elkady H, Gobaara IMM, Alsfouk BA, Husein DZ et al (2022) Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: in vitro anticancer and VEGFR-2 inhibitory effects. Molecules 27(14):4606", "ArticleIdList": ["35889478", "9317904", "10.3390/molecules27144606"]}, {"Citation": "Taghour MS, Elkady H, Eldehna WM, El-Deeb NM, Kenawy AM, Elkaeed EB et al (2022) Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: in-vitro anticancer evaluation and in-silico studies. J Enzym Inhib Med Chem 37(1):1903\u20131917", "ArticleIdList": ["10.1080/14756366.2022.2085693"]}, {"Citation": "O\u2019Toole SA, Sheppard BL, McGuinness EP, Gleeson NC, Yoneda M, Bonnar JJCD et al (2003) The MTS assay as an indicator of chemosensitivity/resistance in malignant gynaecological tumours. Cancer Detect Prev 27(1):47\u201354", "ArticleIdList": ["12600417", "10.1016/S0361-090X(02)00171-X"]}, {"Citation": "Koch A, Tamez P, Pezzuto J, Soejarto D (2005) Evaluation of plants used for antimalarial treatment by the Maasai of Kenya. J Ethnopharmacol 101(1\u20133):95\u201399", "ArticleIdList": ["15878245", "10.1016/j.jep.2005.03.011"]}, {"Citation": "Rodriguez LG, Wu X, Guan J-L (2005) Wound-healing assay. Cell Migr 23\u201329"}, {"Citation": "Collins TJ (2007) ImageJ for microscopy. Biotechniques 43(S1):S25\u2013S30"}, {"Citation": "Kasibhatla S, Amarante-Mendes GP, Finucane D, Brunner T, Bossy-Wetzel E, Green DR (2006) Acridine orange/ethidium bromide (AO/EB) staining to detect apoptosis. Cold Spring Harbor Protoc 3:4493", "ArticleIdList": ["10.1101/pdb.prot4493"]}, {"Citation": "Taylor S, Wakem M, Dijkman G, Alsarraj M, Nguyen M (2010) A practical approach to RT-qPCR\u2014publishing data that conform to the MIQE guidelines. Methods 50(4):S1\u2013S5", "ArticleIdList": ["20215014", "10.1016/j.ymeth.2010.01.005"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "1", "Day": "22"}, {"Year": "2023", "Month": "3", "Day": "29"}, {"Year": "2024", "Month": "7", "Day": "26", "Hour": "12", "Minute": "33"}, {"Year": "2023", "Month": "5", "Day": "10", "Hour": "12", "Minute": "42"}, {"Year": "2023", "Month": "5", "Day": "10", "Hour": "11", "Minute": "12"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37162644", "10.1007/s11030-023-10644-4", "10.1007/s11030-023-10644-4"]}}], "PubmedBookArticle": []}